<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688788</url>
  </required_header>
  <id_info>
    <org_study_id>DanNORMS_version 2.2</org_study_id>
    <nct_id>NCT04688788</nct_id>
  </id_info>
  <brief_title>Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis</brief_title>
  <acronym>DanNORMS</acronym>
  <official_title>Danish Non-inferiority Study of Ocrelizumab and Rituximab in MS (DanNORMS): A Randomized Study Comparing the Efficacy of Ocrelizumab and Rituximab in Active Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hillerod Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kolding Sygehus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regional Hospital Holstebro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital of South West Jutland, Esbjerg, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GCP unit, Copenhagen University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GCP-unit at Aarhus University Hospital, Aarhus, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital of Southern Jutland, Sønderborg, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital of Central Denmark Region, Viborg, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danske Regioner</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DanNORMS study is phase 3 non-inferiority clinical trial examining whether treatment of&#xD;
      active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy&#xD;
      and safety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The DanNORMS study will include patients with active multiple sclerosis aged 18-65 years.&#xD;
      Patients will be randomized in a 2:1 ratio to either rituximab or ocrelizumab. The study&#xD;
      duration is 24 months, and patients can continue in an extension phase for additional 36&#xD;
      month. The primary endpoint is the percentage of patients without new or enlarging T2 white&#xD;
      matter lesions on brain MRI scans from month 6 to month 24, which will be assessed by&#xD;
      radiologists blinded to the treatments status. The study will evaluate a number of efficacy&#xD;
      and safety endpoints using clinical, MRI, routine blood samples and research biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">April 28, 2028</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective, 2:1 randomized, open-label, multi-centre, phase 3 non-inferiority clinical trial with blinded primary endpoint.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>MRI scan data will be transfered to the MRI Reader Centre with pseudonymized identity and without any information regarding the treatment allocation of the patient.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients without new or enlarging T2 white matter lesions on brain MRI scans</measure>
    <time_frame>Month 6 to month 24</time_frame>
    <description>MRI outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with 6-month confirmed disability progression (CDP) in Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>Baseline to month 24</time_frame>
    <description>Clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualised relapse rate based on cumulative number of confirmed relapses from baseline to months 24</measure>
    <time_frame>Baseline to month 24</time_frame>
    <description>Clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with 6-months CDP in Timed 25 Foot Walk (T25FW)</measure>
    <time_frame>Baseline to month 24</time_frame>
    <description>Clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with 6-months CDP in 9-Hole-Peg Test (9HPT)</measure>
    <time_frame>Baseline to month 24</time_frame>
    <description>Clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with 6-months CDP in Symbol Digit Modalities Test (SDMT)</measure>
    <time_frame>Baseline to month 24</time_frame>
    <description>Clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multiple Sclerosis Impact Scale (MSIS-29)</measure>
    <time_frame>Baseline to month 24</time_frame>
    <description>Patient related outcome measure (PROM). A 29 item questionnaire with values ranging from 29 (good) to 145 (worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fatigue Scale for Motor and Cognitive Functions (FSMC)</measure>
    <time_frame>Baseline to month 24</time_frame>
    <description>PROM. A 20 item questionnaire with values ranging from 20 (no fatigue at all) and 100 (severest grade of fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol- 5 Dimension (EQ-5D)</measure>
    <time_frame>Baseline to month 24</time_frame>
    <description>PROM. A 5 item questionnaire with values ranging from 5 (good) to 15 (worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients without gadolinium-enhancing lesions (GdEL)</measure>
    <time_frame>Month 6 and month 24 MRI scans</time_frame>
    <description>MRI outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in T2 white matter lesion volume</measure>
    <time_frame>From month 6 to month 24</time_frame>
    <description>MRI outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in T1 white matter lesion volume</measure>
    <time_frame>From month 6 to month 24</time_frame>
    <description>MRI outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage brain volume change (PBVC) from month 6 to month 24</measure>
    <time_frame>From month 6 to month 24</time_frame>
    <description>MRI outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum neurofilament light chain level</measure>
    <time_frame>From baseline to month 24</time_frame>
    <description>Blood biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood levels of cluster of differentiation antigen 19 (CD19)+ B cells</measure>
    <time_frame>At month 6 and month 24</time_frame>
    <description>Blood biomarker</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Antidrug antibody frequency</measure>
    <time_frame>Baseline, month 6 and month 24</time_frame>
    <description>Anti drug antibodies against rituximab or ocrelizumab</description>
  </other_outcome>
  <other_outcome>
    <measure>Drug concentration</measure>
    <time_frame>Month 6 and month 24</time_frame>
    <description>Rituximab or ocrelizumab drug concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Genotyping of Fc gamma receptor type IIA and IIIA (FCRGIIA and FCGRIIIA), Complement C1q A Chain (C1QA) and low-density lipoprotein receptor-related protein 2 (LRP2)</measure>
    <time_frame>Baseline</time_frame>
    <description>Genotypes associated with rituximab efficacy and safety (FCRGIIA 131, FCGRIIIA 158, C1QA 276) and relapse frequency (LRP2)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">594</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <condition>Secondary Progressive Multiple Sclerosis</condition>
  <condition>Primary Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous biosimilar rituximab (Ruxience®) 1000 mg given every 6th month (first 2 infusions 1000mg/1000 mg given 2 weeks apart).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ocrelizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous ocrelizumab (Ocrevus®) 600 mg every 6th month (first 2 infusions 300 mg/300 mg given 2 weeks apart).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab is a chimeric mouse/human monoclonal immunoglobulin gamma-1 (IgG1) antibody which depletes cluster of differentiation antigen 20 (CD20)-positive cells. Rituximab is approved for non-hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangitis and microscopic polyangitis, and pemphigus vulgaris.</description>
    <arm_group_label>Rituximab</arm_group_label>
    <other_name>Ruxience</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ocrelizumab</intervention_name>
    <description>Ocrelizumab is a recombinant humanised monoclonal IgG1 antibody which depletes CD20-positive cells. Ocrelizumab is approved for multiple sclerosis.</description>
    <arm_group_label>Ocrelizumab</arm_group_label>
    <other_name>Ocrevus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine</intervention_name>
    <description>Premedication with oral fexofenadine 360 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.</description>
    <arm_group_label>Ocrelizumab</arm_group_label>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Premedication with oral. paracetamol 1000 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.</description>
    <arm_group_label>Ocrelizumab</arm_group_label>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Premedication with oral methylprednisolone 100 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.</description>
    <arm_group_label>Ocrelizumab</arm_group_label>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  MS diagnosis and definition of disease course according to the 2017 McDonald criteria&#xD;
&#xD;
          -  Expanded disability status scale (EDSS) ≤6.5&#xD;
&#xD;
          -  Fulfilling criteria for active MS:&#xD;
&#xD;
               -  Treatment naïve relapsing remitting multiple sclerosis (RRMS) patients (never&#xD;
                  treated, or no DMT the previous 2 years):&#xD;
&#xD;
                    1. ▪≥2 relapse previous 12 months OR&#xD;
&#xD;
                    2. 1 relapse previous 12 months with severe residual symptoms and EDSS ≥ 3.0 OR&#xD;
&#xD;
                    3. 1 relapse previous 12 months AND ≥9 T2 lesions on brain and/or spinal cord&#xD;
                       MRI AND&#xD;
&#xD;
                         -  1 contrast-enhancing lesion or ≥1 new or enlarging T2 lesion on brain&#xD;
                            and/or spinal cord MRI previous 12 month&#xD;
&#xD;
               -  Previously treated RRMS patients:&#xD;
&#xD;
                    1. ≥1 relapse previous 12 months OR&#xD;
&#xD;
                    2. ≥1 contrast-enhancing lesion or ≥2 new/enlarging T2 lesions on brain and/or&#xD;
                       spinal cord MRI previous 12 months&#xD;
&#xD;
               -  Progressive MS patients:&#xD;
&#xD;
                    1. ≥1 relapse previous 12 months OR&#xD;
&#xD;
                    2. ≥1 contrast-enhancing lesion previous 12 months or ≥1 new/enlarging T2&#xD;
                       lesions on brain and/or spinal cord MRI previous 12 months or ≥2 new or&#xD;
                       enlarging T2 lesion on brain and/or spinal cord MRI previous 24 months OR&#xD;
&#xD;
                    3. Increased levels of neurofilament light chain (NFL) in serum or&#xD;
                       cerebrospinal fluid (CSF) in sample collected previous 12 months.&#xD;
                       Progressive MS patients not fulfilling the clinical/MRI criteria for active&#xD;
                       disease, may qualify for inclusion in the study if:&#xD;
&#xD;
                       (A) CSF NFL level (measured with NF-Light® ELISA assay from Uman Diagnostics&#xD;
                       or Simoa):&#xD;
&#xD;
                         -  18 to 40 years &gt;560 ng/l&#xD;
&#xD;
                         -  41 to 60 years &gt;890 ng/l&#xD;
&#xD;
                         -  61 to 65 years &gt;1850 ng/l&#xD;
&#xD;
                       or&#xD;
&#xD;
                       (B) Serum NFL level (measured with Simoa™ NF-light® Advantage Kit)&#xD;
&#xD;
                         -  18 to 20 years &gt;7.4 ng/l&#xD;
&#xD;
                         -  21 to 30 years &gt;9.9 ng/l&#xD;
&#xD;
                         -  31 to 40 years &gt;13.1 ng/l&#xD;
&#xD;
                         -  41 to 50 years &gt;17.5 ng/l&#xD;
&#xD;
                         -  51 to 60 years &gt;23.3 ng/l&#xD;
&#xD;
                         -  61 to 75 years &gt;30.9 ng/l&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Lack of effective contraception for women of child-bearing potential (effective&#xD;
             contraception include oral contraception, intrauterine devices and other forms of&#xD;
             contraception with failure rate &lt;1%)&#xD;
&#xD;
          -  Receipt of a live or live-attenuated vaccine within 6 weeks prior to randomization&#xD;
&#xD;
          -  Known active malignant disease&#xD;
&#xD;
          -  Severe heart failure (New York Heart Association Class IV) or severe, uncontrolled&#xD;
             cardiac disease&#xD;
&#xD;
          -  Positive test for HIV, hepatitis B or C, or tuberculosis&#xD;
&#xD;
          -  Negative test for varicella zoster&#xD;
&#xD;
          -  Lymphopenia grade 2 (0.5 to 0.8 × 10^9/L) or higher grades of lymphopenia (in case of&#xD;
             switching from fingolimod lymphopenia grade 2 can be accepted if lymphocytes are&#xD;
             rising markedly compared to on treatment levels)&#xD;
&#xD;
          -  Neutropenia grade 2 (1.0 to 1.5 × 10^9/L) or higher grades&#xD;
&#xD;
          -  Thrombocytopenia grade 2 (50 to 75 × 10^9/L) or higher grades&#xD;
&#xD;
          -  Previous treatment with alemtuzumab or hematopoietic stem-cell transplantation&#xD;
&#xD;
          -  Previous treatment with cladribine, CD20-depleting antibodies, daclizumab or other&#xD;
             immune suppressive treatment which is judged to still exert immune suppressive effect&#xD;
             by treating physician&#xD;
&#xD;
          -  Methylprednisolone treatment within 1 month of baseline visit&#xD;
&#xD;
          -  Findings on the screening MRI judged to preclude participation by the treating&#xD;
             physician&#xD;
&#xD;
          -  Other diseases judged to be relevant by the treating physician&#xD;
&#xD;
          -  Contraindication to MRI&#xD;
&#xD;
          -  Known allergy or hypersensitivity to rituximab or ocrelizumab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeppe Romme Christensen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Multiple Sclerosis Center Rigshospitalet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeppe Romme Christensen, MD, PhD</last_name>
    <phone>0045 38633379</phone>
    <email>jeppe.romme.christensen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Finn Sellebjerg, Prof., MD, PhD</last_name>
    <phone>0045 38633236</phone>
    <email>finn.thorup.sellebjerg@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Danish Multiple Sclerosis Center, Rigshospitalet</name>
      <address>
        <city>Glostrup</city>
        <state>Copenhagen</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeppe Romme Christensen, MD, PhD</last_name>
      <phone>0045 38633379</phone>
      <email>jeppe.romme.christensen@rh.regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia C Hilt, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Morten Stilund, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Hospital of South West Jutland, Esbjerg</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tobias Sejbæk, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arkadiusz Weglewski, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Nordsjællands Hospital i Hillerød</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mai B Poulsen, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Regionshospitalet Holstebro</name>
      <address>
        <city>Holstebro</city>
        <zip>7500</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Morten Stilund, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Kolding Hospital</name>
      <address>
        <city>Kolding</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henrik Boye Jensen, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zsolt Illes, Prof., MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Sjællands Universitetshospital, Roskilde</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lena Roug, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Hospital of Southern Jutland, Sønderborg</name>
      <address>
        <city>Sønderborg</city>
        <zip>6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Kant, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of neurology, Regionshospitalet Viborg</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sivagini Prakash, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Jeppe Romme Christensen</investigator_full_name>
    <investigator_title>National coordinating principal investigator</investigator_title>
  </responsible_party>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Ocrelizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Ocrelizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

